Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Update

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 25 shares, a growth of ? from the May 31st total of 0 shares. Based on an average daily volume of 8,277 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Appili Therapeutics Stock Performance

Shares of APLIF remained flat at $0.01 during trading hours on Thursday. The stock had a trading volume of 400 shares, compared to its average volume of 15,602. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.03. The company has a market capitalization of $1.34 million, a PE ratio of -0.25 and a beta of -0.03. The firm’s 50 day simple moving average is $0.01 and its 200 day simple moving average is $0.01.

Appili Therapeutics (OTCMKTS:APLIF) last released its earnings results on Friday, June 26th. The company reported $999.00 EPS for the quarter. The firm had revenue of $0.03 million during the quarter.

About Appili Therapeutics

Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.

Appili’s product pipeline features multiple candidates in various stages of development.